The first-ever clinical practice guideline for the drug treatment of obesity offers a new tool for health practitioners looking to the latest pharmacotherapy strategies as a means of treating patients with obesity. The release comes on the heels of U.S. Food and Drug Administration (FDA) approval of four new anti-obesity drugs in the past two years — lorcaserin (Belviq), phentermine/topiramate (Qsymia), naltrexone/bupropion (Contrave) and liraglutide (Saxenda). The guideline, “Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline,” is published by the Endocrine Society, with support from The Obesity Society (TOS) and the European Society of Endocrinology.
“The pharmacotherapy guideline provides a roadmap for clinicians considering anti-obesity drug treatment for patients not finding success with diet and exercise alone,” says Donna Ryan, MD, member of the development panel and professor emeritus at Louisiana State University’s Pennington Biomedical Research Center, speaking on behalf of TOS. “The new guideline provides doctors with recommended medications and dosage based on obesity-related comorbidities, including type 2 diabetes and cardiovascular disease. Further, it gives specific recommendations for transitioning patients off drugs that cause weight gain, shifting the treatment paradigm from treating weight last, to treating weight first.”
The Endocrine Society further highlights key recommendations from the guideline, including: implications for continuing and discontinuing medication, guidance for prescribing medications that promote weight loss or have no effect on weight, and disclosure of information about medication-related weight gain to patients to promote shared decision making.
As the first pharmacotherapy guideline for the treatment of obesity, the new resource expands upon the “Guidelines (2013) for Managing Overweight and Obesity in Adults,” published in Obesity in November 2013 by TOS, the American Heart Association (AHA) and the American College of Cardiology (ACC).
“The 2013 Guidelines help health practitioners identify patients who may benefit from pharmacotherapy, and the new pharmacological guideline can help them decide on the best anti-obesity drug option,” continued Dr. Ryan. “Combined, both resources fill a gap in the treatment of obesity, a disease that puts individuals at risk for more than 30 other health conditions, including type 2 diabetes and cardiovascular disease.”
Seeking the support of a healthcare practitioner for weight loss can make all the difference for people affected by obesity. As an adjunct to diet and exercise, medications approved by the FDA for the treatment of obesity can help those affected to lose weight, specifically if they have not found prior success with diet and exercise alone. Taken together, both guidelines provide an evidence-based tool to help physicians identify and treat patients struggling with their weight that may need the additional support.
“We call on prescribing health practitioners from primary care physicians to bariatric surgeons to review both guidelines and take steps to put them into practice,” concludes Dr. Ryan. “Broad, sweeping transformations in obesity management in the primary care setting can help identify patients most in need of this additional support.”
Fitness News — Sciencedaily
— Courtesy “Science News Daily” (ScienceNewsDaily.com)
Recovering from Hip Replacement Surgery involves following a clear EXERCISE PROGRAMME. This video is an OVERVIEW of the Exercise Programme we recommend at th…
The Perfect Daniel Plan Companion for Better Overall Health Research shows that tracking your food and exercise greatly contributes to your long-term success. Maximize your momentum by exploring and charting your journey through the five key essentials of The Daniel Plan—faith food fitness focus and friends. Taking readers of The Daniel Plan: 40 Days to a Healthier Life to the next level The Daniel Plan Journal is the perfect companion providing encouraging reminders about your health. On the days you need a little boost The Daniel Plan Journal has the daily Scripture inspiration and motivation you need to stay on track and keep moving forward.
- Super – Christian Living.
- Primary – Practical Life.
- Sub – Diet and Health.
- Author – Warren Rick.
- Hardcover – 208 pages.
- Publisher – Zondervan; The Daniel Plan edition (December 3 2013).
- Language – English.
About the Author
Dr. Rick Warren is pastor author global strategist theologian and philanthropist. His book The Purpose driven Life has been called the bestselling non-fiction hardback in publishing history by Publishers Weekly having sold more than 32 million copies. Warren founded Saddleback Church in 1980 with his wife Kay. In addition to a 120-acre campus in Lake Forest CA the church has ten satellite campuses in Southern California and three international campuses.
Perplexus is a maze game where players must maneuver a small marble around challenging barriers inside a transparent sphere. Unlike traditional flat-surface mazes that are composed of one path, Perplexus houses various exhilarating tracks with 100 barriers and provides a three dimensional experience. Players select which track they would like to attempt, and then must work with gravity and carefully shift, flip, and twist the sphere to guide the marble. Players can race each other or the clock. On top of being entertaining, Perplexus is also an educational toy, and assists in child development. It is a great toy for children to exercise their motor and dexterity skills, as well as improve their hand-eye coordination. Its small size makes it easily portable. No batteries required.
Price: $ 24.99
Sold by drugstore.com